AZAlan Zeng

Alan Zeng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alan Zeng has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Allen C. Gao

    Department of Urologic Surgery, University of California, Davis, Sacramento, CA 95817, USA

    1 shared publication
  • Boyang Jason Wu

    Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, USA

    1 shared publication
  • Eva Corey

    Department of Urology, University of Washington, Seattle, WA 98195, USA

    1 shared publication
  • Jing Wang

    Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA, 99202, USA.

    1 shared publication
  • Jing Wei

    Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA 99202, USA

    1 shared publication
  • Jingjing Li

    Engineering Research Center of Cell & Therapeutic Antibody, School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, China

    1 shared publication

Latest Publications

  • Open Access

    Stromal-derived MAOB promotes prostate cancer growth and progression

    by Tianjie Pu, Jing Wang, Jing Wei, Alan Zeng, Jinglong Zhang, Jingrui Chen, Lijuan Yin, Jingjing Li, Tzu-Ping Lin, Jonathan Melamed, et al.

    Prostate cancer (PC) develops in a microenvironment where the stromal cells modulate adjacent tumor growth and progression. Here, we demonstrated elevated levels of monoamine oxidase B (MAOB), a mitochondrial enzyme that degrades biogenic and dietary monoamines, in human PC stroma, which was associated with poor clinical outcomes of PC patients. Knockdown or overexpression of MAOB in human prostate stromal fibroblasts indicated that MAOB promotes cocultured PC cell proliferation, migration, and invasion and co-inoculated prostate tumor growth in mice. Mechanistically, MAOB induces a reactive stroma with activated marker expression, increased extracellular matrix remodeling, and acquisition of a protumorigenic phenotype through enhanced production of reactive oxygen species. Moreover, MAOB transcriptionally activates CXCL12 through Twist1 synergizing with TGFβ1-dependent Smads in prostate stroma, which stimulates tumor-expressed CXCR4-Src/JNK signaling in a paracrine manner. Pharmacological inhibition of stromal MAOB restricted PC xenograft growth in mice. Collectively, these findings characterize the contribution of MAOB to PC and suggest MAOB as a potential stroma-based therapeutic target.